Geodon Uses: What Ziprasidone Treats, How It Works, and What to Expect
Author:
Blossom Editorial
Geodon is the brand name for ziprasidone, a second-generation antipsychotic that the U.S. Food and Drug Administration first approved in 2001. It is prescribed mainly for schizophrenia and for bipolar I disorder, and an injectable version is used in hospitals to settle severe agitation quickly.
If you or someone you care about has been offered this medication, it helps to know what it treats, how it is typically dosed, and which side effects deserve attention. Below are the approved Geodon uses, the common off-label ones, and the safety points that can make ziprasidone a little different from other medications in its class.
Key Takeaways
Geodon oral capsules have three approved uses in adults: Schizophrenia, acute manic or mixed episodes of bipolar I disorder, and long-term maintenance of bipolar I disorder alongside lithium or valproate. A short-acting, intramuscular injection is separately approved for the rapid treatment of acute agitation in adults with schizophrenia.
Food can change how much medication reaches your bloodstream: Absorption of ziprasidone may increase twofold (bioavailability of 60-70%) when the capsule is taken with a meal that’s approximately 500 kcal or more, which is why the prescribing information instructs patients to take it with food twice a day.
Heart rhythm may warrant closer attention with Geodon than with most alternatives: Ziprasidone can lengthen the QT interval more than several other antipsychotics, so prescribers usually review heart history and current medications first. It also tends to be gentler on weight and metabolism than many drugs in its class.
What is Geodon (Ziprasidone)?
Geodon is the brand name for ziprasidone, a prescription medication in a group of drugs called atypical or second-generation antipsychotics. Doctors use antipsychotics to treat conditions that involve psychosis, severe mood swings, or both. Despite the name, these medications are used for far more than psychosis alone.
The FDA prescribing information lists Geodon as oral capsules in 20 mg, 40 mg, 60 mg, and 80 mg strengths, plus a 20 mg/ml single-dose vial for intramuscular injection. Ziprasidone is also widely available as a lower-cost generic, which is what most pharmacies dispense today.
One practical detail sets ziprasidone apart from many psychiatric medications: it is taken twice a day rather than once, and it should be taken with food. Both of those requirements trace back to how the drug is absorbed.
FDA-Approved Geodon Uses
The FDA has cleared Geodon for four specific situations in adults, three of them involving the oral capsules and one involving the injection. The approvals rest on placebo-controlled clinical trials submitted by the manufacturer.
Schizophrenia
Treating schizophrenia in adults is the original and most common use of Geodon. Schizophrenia is a chronic condition that can involve hallucinations, delusions, disorganized thinking, and a flattening of motivation and emotional expression. The National Institute of Mental Health describes antipsychotic medication as a core part of treatment, usually combined with therapy and support services.
Geodon (ziprasidone) was tested in five placebo-controlled schizophrenia studies, four of them lasting four to six weeks and one designed to see whether it prevented relapse over a longer stretch. Of the five trials, four could establish a distinction between ziprasidone and placebo in terms of response. In the maintenance study, people who stayed on ziprasidone went significantly longer before showing signs of relapse than people who switched to placebo. This is why Geodon is used for ongoing treatment of schizophrenia and not just acute episodes.
Acute Manic or Mixed Episodes in Bipolar I Disorder
Geodon is approved as a standalone acute treatment for adults having a manic or mixed episode of bipolar I disorder. A manic episode involves an elevated or irritable mood, reduced need for sleep, racing thoughts, and impulsive behavior. A mixed episode blends manic energy with depressive symptoms at the same time.
Two three-week clinical trials enrolling over 200 adults each found ziprasidone significantly better than placebo at reducing manic symptoms. A separate 21-day randomized replication trial on over 200 inpatients reported that mania scores fell by about 11 points on ziprasidone compared with about 6 points on placebo, with signs of improvement showing up as early as the second day of treatment. That relatively rapid onset may be one reason ziprasidone is sometimes chosen during an acute episode.
It is important to note that although average improvements in manic symptoms became statistically detectable as early as the second day of treatment, full therapeutic effects generally continue to develop over subsequent weeks.
Manic and mixed episodes can be mistaken for other conditions like ADHD, which is why an accurate diagnosis often takes more than one appointment.
Maintenance Treatment for Bipolar I Disorder
The third approved use is longer-term prevention. Here, Geodon (ziprasidone) is added to mood stabilizers, including lithium or valproate, rather than used alone. Lithium and valproate belong to a class of bipolar medications called mood stabilizers that are generally used for long-term maintenance treatment of bipolar disorder.
In the clinical trial supporting this indication, adults were first stabilized on ziprasidone plus a mood stabilizer for at least eight weeks, then randomly assigned to keep taking ziprasidone or switch to placebo. Those who continued ziprasidone went longer before a new mood episode (manic, mixed, or depressive) required intervention.
Interestingly, depressive episodes accounted for about half of relapse events in the maintenance study, highlighting the importance of preventing both manic and depressive recurrences in bipolar disorder. However, this finding does not necessarily mean that ziprasidone has direct antidepressant effects.
Acute Agitation in Schizophrenia (Injection Form)
The intramuscular form of Geodon is used in emergency rooms and inpatient units when someone with schizophrenia becomes acutely agitated and needs rapid relief. The typical dose is 10 mg to 20 mg, with a ceiling of 40 mg in a day and a minimum gap of 2 hours between 10 mg injections and 4 hours between 20 mg injections. The label notes that injectable use beyond three consecutive days has not been studied. Once the situation stabilizes, treatment usually switches to oral capsules.
The label also cautions that Geodon must only be administered via intramuscular injection and not intravenously.
Off-Label Geodon Uses
Prescribers sometimes use Geodon for conditions outside its formal approvals. Off-label prescribing is legal and common in psychiatry, but it means the FDA has not reviewed evidence for that specific use, so the supporting research is often smaller or less consistent.
Reported off-label uses of Geodon (ziprasidone) may include:
Treatment-resistant depression, usually as an add-on to an antidepressant
Hypomania associated with bipolar II disorder
Management of severe agitation associated with delirium in selected hospitalized patients (although evidence for improving delirium itself is limited, and routine use is not recommended by current guidelines)
Agitation or aggression related to substance intoxication or other medical causes
Delusional parasitosis, a rare condition involving a fixed belief of infestation
A small randomized trial also tested Geodon for depressive episodes that carry a few manic features, and found a benefit over placebo. That said, this remains an area where evidence is limited and clinical judgment matters a great deal.
How Geodon Works in the Brain
Like other atypical antipsychotics, Geodon acts on two neurotransmitter systems at once. It blocks dopamine D2 receptors, which is thought to reduce hallucinations, delusions, and manic symptoms. It also blocks serotonin 5-HT2A receptors, which may soften the movement side effects that older antipsychotics were known for.
Geodon has a few extra properties that set it apart. It acts as an agonist at the 5-HT1A serotonin receptor and has relatively weak serotonin and norepinephrine reuptake inhibition compared with antidepressants. This broader receptor profile may be one reason Geodon behaves differently from other drugs in its class, though how much it contributes to real-world outcomes is not fully understood.
Geodon Dosing: What the Prescribing Information Recommends
Dosing depends on which condition is being treated, and the approved oral uses start at different points. Your prescriber will tailor the plan to your response and tolerance, so treat the numbers below as reference points rather than instructions.
Dosing for Schizophrenia
The label calls for starting at 20 mg twice daily with food. From there, the dose can be raised to 80 mg twice daily based on response. Adjustments are generally spaced at least two days apart, since blood concentrations reach steady state within about one to three days. However, clinical improvement often takes considerably longer.
The prescribing information also advises watching for improvement over several weeks before pushing the dose higher, because a higher number is not automatically a better outcome. In the clinical trials, doses above 80 mg twice daily did not clearly add benefit.
Dosing for Bipolar I Disorder
Mania is treated more assertively at the start. The label recommends 40 mg twice daily with food on the first day, then an increase to 60 mg or 80 mg twice daily on day two, with subsequent adjustments staying within a range of 40 mg to 80 mg twice daily based on effectiveness and tolerance. In the flexible-dose clinical trials for manic episodes, the average total daily doses were 112 mg and 132 mg.
For maintenance treatment, people generally stay on whatever dose stabilized them, within the 40 mg to 80 mg twice daily range, while continuing lithium or valproate.
Why Geodon Must Be Taken With Food
This may be the most practical detail to know about Geodon (ziprasidone). The FDA label states that absorption increases up to two-fold in the presence of food. In percentage terms, the drug’s bioavailability when taken with food is between 60-70%. Taking a capsule on an empty stomach can leave you with substantially less drug exposure than you would get otherwise, which may look like the medication simply is not working.
Because of this, prescribers usually recommend pairing each dose with a meal of approximately 500 calories or more, since smaller meals may not produce the same increase in absorption, and keeping the timing consistent day to day. Capsules should be swallowed whole and not opened, crushed, or chewed.
Geodon Side Effects
Side effect patterns differ somewhat depending on whether Geodon is being used for schizophrenia or for mania, partly because the doses and the illnesses themselves differ. The figures below are based on results from the placebo-controlled trials published in the FDA label.
Common Side Effects
In short-term schizophrenia trials, the reactions that showed up in at least 5% of people and at least twice as often as with placebo were somnolence (sleepiness) and respiratory tract infection. Sleepiness was reported by about 14% of people on Geodon compared with about 7% on placebo.
Nausea, constipation, indigestion, and dry mouth also appeared, though at rates closer to placebo.
In the bipolar mania trials, side effects were reported more often. Roughly 31% of participants reported sleepiness compared with about 12% on placebo, and dizziness was reported by about 16% compared with 7%. Headache was almost equally common in both groups.
Movement-Related Side Effects
Antipsychotics can cause muscle stiffness and spasms, tremor, restlessness, and other movement changes, grouped together as extrapyramidal symptoms. In schizophrenia trials, these were reported by about 14% of Geodon users versus 8% of placebo users. In mania trials, the gap was wider, about 31% versus 12%.
Akathisia, an uncomfortable inner restlessness that makes it hard to sit still, is worth flagging to your prescriber early. It is treatable, but it is also a common reason people stop taking antipsychotics without telling anyone.
Tardive dyskinesia, a syndrome of involuntary, repetitive movements that may not fully reverse, is a risk with all antipsychotics, especially for elderly women. Risk tends to rise with longer treatment and higher cumulative doses, which is part of why prescribers aim for the lowest effective dose.
Weight and Metabolic Effects
This is where Geodon tends to compare favorably to other second-generation antipsychotics. In pooled short-term schizophrenia trials, about 10% of people on Geodon gained at least 7% of their body weight, compared with about 4% on placebo, with a median gain of roughly half a kilogram. In the bipolar trials, clinically meaningful weight gain (>7% of body weight) occurred in about 2-4% of participants versus about 2% on placebo.
By comparison, the mean weight gain over a 10-week treatment period with standard doses of antipsychotic medications clozapine and olanzapine was 4.45 kg and 4.15 kg, respectively.
The label also notes that people who started at a lower body mass index gained the most, while people who started at a higher body mass index tended to lose a small amount of weight on average. Blood sugar and cholesterol changes in the trials were modest and often similar to placebo, though the FDA still recommends monitoring, since the whole antipsychotic class carries some metabolic risk.
Serious Side Effects That Need Immediate Attention
Certain reactions are rare but require prompt medical care. Contact your provider or seek emergency care if you experience:
A rash of any kind, particularly with fever, facial swelling, or swollen glands, which can signal a severe skin reaction
High fever with muscle rigidity, confusion, and an irregular pulse, which can indicate neuroleptic malignant syndrome
Fainting, palpitations, or unexplained dizziness, which may relate to heart rhythm
Agitation, tremor, sweating, rapid heart rate, and confusion together, which can signal a rare but serious condition called serotonin syndrome, particularly when the medication is combined with other drugs that increase serotonin levels
Fever or repeated infections, which may reflect a drop in white blood cell counts
About 5% of people in premarketing trials developed a rash or hives, and the label advises stopping Geodon if a rash appears without another clear explanation.
Geodon and Heart Rhythm: Understanding the QT Warning
This deserves its own section because it shapes how Geodon (ziprasidone) is prescribed. The QT interval is a measurement on an electrocardiogram that reflects how long the heart takes to recharge between beats. When it stretches too far, the risk of a dangerous rhythm called torsade de pointes goes up.
In a study comparing several antipsychotics head to head, ziprasidone lengthened the QT interval by roughly 9 to 14 milliseconds more than risperidone (Risperdal), olanzapine (Zyprexa), quetiapine (Seroquel), and haloperidol (Haldol), although it was about 14 milliseconds less than thioridazine. At the highest recommended daily dose of 160 mg, ziprasidone increased the interval by about 10 milliseconds compared with placebo.
Two points of context matter here. Torsade de pointes was not observed in the premarketing studies, and readings above the clinically concerning threshold of 500 milliseconds were rare. At the same time, because ziprasidone prolongs the QT interval more than many other atypical antipsychotics, clinicians may prefer alternative medications in patients with known risk factors for serious heart rhythm problems.. This is worth raising directly with your prescriber rather than trying to weigh on your own.
Low potassium or magnesium can amplify the risk, so baseline blood work is sometimes ordered before starting, particularly for people taking diuretics.
Who Should Not Take Geodon
The prescribing information lists several situations where ziprasidone should not be used at all:
A known history of QT prolongation, including congenital long QT syndrome
A recent heart attack
Uncompensated heart failure
Simultaneously with other medications known to prolong the QT interval
A known allergy to ziprasidone
Concurrently with a monoamine oxidase inhibitor, or use within the past 14 days
Geodon also carries a boxed warning, the FDA’s strongest, stating that older adults with dementia-related psychosis who take antipsychotics face an increased risk of death. Geodon is not approved for that use. Safety and effectiveness have also not been established in children and teenagers.
How Geodon Compares to Other Antipsychotics
No antipsychotic is best for everyone, and the trade-offs tend to fall along predictable lines. Ziprasidone produces little weight gain and is the only second-generation antipsychotic not associated with metabolic syndrome (high blood sugar, hypertension, abnormal cholestrol and triglyceride levels). However, the drug can prolong the QTc interval, which is close to the inverse of the profile seen with some alternatives.
While all atypical antipsychotics can be effective, studies suggest some medications, including olanzapine and risperidone, may produce slightly greater reductions in acute manic symptoms at the cost of greater metabolic side effects. Aripiprazole (Abilify) sits somewhere in between and is sometimes chosen when sedation is a concern.
For bipolar disorder specifically, mood stabilizers such as lamotrigine (Lamictal) play a different role, targeting the depressive side more than the manic one.
There is no head-to-head trial that settles which of these is best. The right choice usually comes down to your medical history, which side effects are more concerning, and what has or has not worked before.
When to Talk With a Psychiatrist About Geodon
Antipsychotics require real monitoring, and that works best with a prescriber who knows your history. It is worth reaching out if symptoms are not improving after several weeks at a steady dose, if side effects are interfering with daily life, or if you are considering stopping.
Stopping an antipsychotic abruptly can allow symptoms to return, sometimes quickly, so this is generally a decision to make with your provider, who can help you taper safely or transition to something else.
If you have questions about whether an antipsychotic is right for your situation, a licensed psychiatric provider can review your history and current medications and build a plan with you. You can book a virtual appointment with a Blossom Health provider covered by in-network insurance and usually be seen within days.
Medical Disclaimer
This article is for informational purposes only and is not a substitute for professional medical advice. Always talk with your physician or another qualified healthcare provider about any questions regarding a medical condition or medication. If you are experiencing a mental health crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988.
Sources
U.S. Food and Drug Administration. (2025, January). Geodon (ziprasidone hydrochloride) capsules and Geodon (ziprasidone mesylate) for injection: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020825s065,020919s053lbl.pdf
Bouchette, D., Fariba, K.A., Patel, P., et al. Ziprasidone. [Updated 2024 Feb 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448157/
Willner, K., Vasan, S., Patel, P., et al. Atypical Antipsychotic Agents. [Updated 2024 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448156/
Chokhawala, K.P., Stevens, L. Antipsychotic Medications. [Updated 2023 Feb 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519503/
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Ziprasidone. [Updated 2023 Jun 10]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548663/
Potkin, S. G., Keck, P. E., Jr, Segal, S., Ice, K., & English, P. (2005). Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. Journal of clinical psychopharmacology, 25(4), 301–310. https://pubmed.ncbi.nlm.nih.gov/16012271/
Patkar, A., Gilmer, W., Pae, C. U., Vöhringer, et al. (2012). A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PloS one, 7(4), e34757. https://pmc.ncbi.nlm.nih.gov/articles/PMC3335844/
Findling, R. L., Cavuş, I., Pappadopulos, E., et al. (2013). Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder. Journal of child and adolescent psychopharmacology, 23(8), 545–557. https://pmc.ncbi.nlm.nih.gov/articles/PMC3804078/
National Institute of Mental Health. (2024, December). Schizophrenia. U.S. Department of Health and Human Services, National Institutes of Health. https://www.nimh.nih.gov/health/topics/schizophrenia
National Institute of Mental Health. (2024, December). Bipolar disorder. U.S. Department of Health and Human Services, National Institutes of Health. https://www.nimh.nih.gov/health/topics/bipolar-disorder
